Navigation Links
Osteopontin: a useful biomarker in asbestos-related cancer

Pleural mesothelioma is an asbestos-related cancer that invades the chest cavity and the lining of the lungs. Workers at risk for high levels of exposure are miners, factory workers, carpenters, electricians//, ship fitters, ships' electricians, boilermakers, insulation manufacturers, railroad workers, gas-mask manufacturers, and pipe insulators.

Recently, a study, published in the October 13 issue of New England Journal of Medicine, was conducted to test the hypothesis that osteopontin is a useful biomarker in pleural mesothelioma and, more specifically, to compare serum levels of osteopontin in a cohort of subjects with asbestos-related biomarker disease with preoperative levels in patients with surgically treated pleural mesothelioma. Osteopontin is a glycoprotein that is over expressed in lung, breast, colorectal, gastric, and ovarian cancer and in melanoma. High levels of osteopontin have previously been shown to correlate with tumor invasion, progression, and metastases.

The researchers investigated the presence of osteopontin in pleural mesothelioma and determined serum osteopontin levels in three populations: subjects without cancer who were exposed to asbestos, subjects without cancer who were not exposed to asbestos, and patients with pleural mesothelioma who were exposed to asbestos.

For the study, a group of 69 subjects with asbestos-related nonmalignant pulmonary disease were compared with 45 subjects without exposure to asbestos and 76 patients with surgically staged pleural mesothelioma. Tumor tissue was examined for osteopontin by immunohistochemical analysis, and serum osteopontin levels were measured by an enzyme-linked immunosorbent assay.

Serum osteopontin levels were found to be significantly higher in the group with pleural mesothelioma than in the group with exposure to asbestos. Immunohistochemical analysis revealed osteopontin staining of the tumor cells in 36 of 38 samples of pleural mesothelioma.
Data from this study suggest that serum osteopontin levels could be used to discriminate between persons with exposure to asbestos who do not have early pleural mesothelioma and those with exposure to asbestos who do have early pleural mesothelioma, regardless of the histologic type of the mesothelioma.

The authors point out that the most important result of this study is the apparent ability of an enzyme-linked immunosorbent assay (ELISA) for osteopontin to identify early pleural mesothelioma (stage I). Also, the finding that osteopontin was present in the tumor cells of pleural mesothelioma and not in the stroma provides support for the specificity of osteopontin as a marker for transformed mesothelial cells. This finding, if confirmed, would have immediate clinical applications, because the use of therapy could potentially influence survival among patients with stage I pleural mesothelioma.
'"/>




Related medicine news :

1. ATG useful in transplant patients as substitute for steroids
2. Vitamin E useful for Alzheimers
3. Carboplatin, Lung cancer drug may be useful in treating breast tumor
4. Vitamin B12 can help in detecting cancers
5. Want skin cancer? Please have a cigarette
6. New hope for cancer victims – will vaccine cure the deadly bug
7. Clintons new problem - Is the outgoing American president suffering from skin cancer?
8. Are cancer patients being taken for a ride?
9. Breast cancer treatment to be determined by gene test
10. Ductal lavage may detect early breast cancer
11. Beware of the oral patch! It could be cancer!!!
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/22/2017)... ... February 22, 2017 , ... ... of a new healthcare contact center in Georgia, PENETRON Specialty Products (PSP) provided ... nation’s largest healthcare systems recently invested $51 million to purchase and renovate the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Stem ... recent years. The technology is so cutting edge, in fact, the U.S. Food ... stem cell procedures. However, successful patient outcomes in certain clinical stem cell procedures ...
(Date:2/22/2017)... ... 2017 , ... The National Academy of Certified Care Managers ... 2017 testing period. NACCM, a nonprofit organization, has provided the premier certification for ... periodically re-calibrated to ensure that newly certified professionals are prepared to work effectively ...
(Date:2/22/2017)... TX (PRWEB) , ... February ... ... Risk Adjustment solution leverages advanced data analytics to accurately understand each Medicare ... proper reimbursement for a given population. This new solution helps transform the ...
(Date:2/22/2017)... ... February 22, 2017 , ... Doctors on Liens is continuing its steady expansion ... H. Rauchman, practicing at North Valley Eye Medical Group in Mission Hills . ... and other personal injury cases. These injuries have a major impact on the ...
Breaking Medicine News(10 mins):
(Date:2/23/2017)... , Feb. 23, 2017  Spheryx, Inc. ... poster presentation at PittCon 2017 Conference and ... is the world,s largest annual premier conference ... a wide array of industry, academic and ... and QA, food safety, environmental, bioterrorism and ...
(Date:2/23/2017)... Provectus Biopharmaceuticals, Inc. (OTCQB: PVCT) ( www.provectusbio.com ... dermatology biopharmaceutical company, today announced that it has appointed ... as special advisers to the Company,s Board of Directors.  ... on financial and corporate strategy. Provectus also ... up to $2.5 million from Eric Wachter , ...
(Date:2/23/2017)... DEERFIELD, Ill. , Feb. 23, 2017 /PRNewswire/ ... a wholly-owned subsidiary of Takeda Pharmaceutical Company Limited (TSE:4502) ... Cognition Holdings PLC and Ctrl Group Limited, announced a ... app on an Apple Watch wearable to monitor and ... (MDD). Depression (MDD) is the leading cause ...
Breaking Medicine Technology: